首页> 外文期刊>Japanese journal of clinical oncology. >Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
【24h】

Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.

机译:导管原位癌和人乳腺浸润性导管癌异步病变杂合性分析的损失。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Ductal carcinoma in situ (DCIS) of the breast is known to possess characteristics of the pre-invasive stage of breast cancer and is the precursor to invasive ductal carcinoma (IDC). However, the natural history of the progression from DCIS to IDC remains unknown at the molecular level. METHODS: We investigated the loss of heterozygosities (LOHs) in tumors of seven patients with a history of breast biopsy. The seven specimens were diagnosed as DCIS on histopathological re-examination. These patients were diagnosed with ipsilateral breast cancer a few years after biopsy. We used thirteen selected microsatellite markers that were mapped to and/or very close to the tumor suppressor genes or regions with frequent LOHs in breast cancer. DNA isolated from microdissected formalin-fixed, paraffin-embedded tissues was subjected to a PCR-LOH analysis for these chromosome loci, and the pattern of LOHs was compared between the two asynchronous lesions for the seven cases. RESULTS: In all patients exceptone, the LOHs were concordant at 91% as the informative chromosome loci in cases 1 to 6 were 56, and the concordance in LOH pattern between DCIS and IDC was detected at 50 loci. The LOHs had accumulated in accordance with the tumor progression from DCIS to IDC. The recurrent lesion occurred at or near the site of the primary biopsy and had similar or identical histopathologic features. CONCLUSIONS: These recurrences observed were probably residual disease rather than true recurrences. Our results suggest the following: (i) genetic alternations accumulate during cancer progression from DCIS to IDC, (ii) DCIS is a lesion that has a high risk of developing invasive transformation and (iii) after approximately 5 years without treatment, DCIS may develop into IDC.
机译:背景:乳腺导管原位癌(DCIS)具有乳腺癌浸润前期的特征,并且是浸润性导管癌(IDC)的前身。但是,从DCIS到IDC的自然发展过程在分子水平上仍然未知。方法:我们调查了7例有乳腺活检史的患者的肿瘤中杂合性(LOHs)的丢失。七个标本经组织病理学复查诊断为DCIS。这些患者在活检几年后被诊断为同侧乳腺癌。我们使用了十三种选择的微卫星标记,这些标记定位于和/或非常接近于乳腺癌中具有频繁LOH的肿瘤抑制基因或区域。从显微解剖的福尔马林固定,石蜡包埋的组织中分离的DNA进行了这些染色体基因座的PCR-LOH分析,并比较了这7例病例在两个异步病变之间的LOHs模式。结果:除1例外,所有患者的LOH一致率为91%,病例1至6的信息染色体位点为56,DCIS和IDC之间LOH模式的一致性为50个位点。 LOH的积累符合肿瘤从DCIS到IDC的进展。复发病变发生在原发活检部位或附近,并具有相似或相同的组织病理学特征。结论:观察到的这些复发可能是残留疾病,而不是真正的复发。我们的研究结果表明:(i)从DCIS到IDC的癌症发展过程中,遗传变异不断累积;(ii)DCIS是具有高度侵袭性转化风险的病变;(iii)未经治疗约5年后,DCIS可能会发展进入IDC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号